197239-49-9

Basic information

• Product Name: 2-FLUORO-4-(TRIFLUOROMETHYL)BENZYL ALCOHOL
• Synonyms: 4-TRIFLUOROMETHYL-2-FLUOROBENZYL ALCOHOL;2-FLUORO-4-(TRIFLUOROMETHYL)BENZYL ALCOHOL;RARECHEM AL BD 0319;2-Fluoro-4-(trifluoromethyl)benzyl alcohol 97%;2-Fluoro-4-(trifluoromethyl)benzylalcohol97%;[2-Fluoro-4-(trifluoromethyl)phenyl]methanol
• CAS NO: 197239-49-9
• Molecular Formula: C₈H₆F₄O
• Molecular Weight: 194.13
• Product Categories: Fluorine series
• Mol File: 197239-49-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 99-101°C 15mm
• Flash Point: 99-101°C/15mm
• Appearance: /
• Density: 1.377
• Vapor Pressure: 0.233mmHg at 25°C
• Refractive Index: 1.447
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.46±0.10(Predicted)
• BRN: 8313249
• CAS DataBase Reference: 2-FLUORO-4-(TRIFLUOROMETHYL)BENZYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-4-(TRIFLUOROMETHYL)BENZYL ALCOHOL(197239-49-9)
• EPA Substance Registry System: 2-FLUORO-4-(TRIFLUOROMETHYL)BENZYL ALCOHOL(197239-49-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 197239-49-9(Hazardous Substances Data)

Usage

General Description

2-Fluoro-4-(trifluoromethyl)benzyl alcohol is a chemical compound with the molecular formula C8H6F4O. It is a benzyl alcohol derivative with a fluorine substitution at the 2-position and a trifluoromethyl group at the 4-position. 2-Fluoro-4-(trifluoromethyl)benzyl alcohol is commonly used as an intermediate in organic synthesis and pharmaceutical research. It is also employed as a reagent in the preparation of various other chemical compounds. Its unique fluorine and trifluoromethyl substituents make it a valuable building block for the creation of complex organic molecules with diverse applications in the chemical and pharmaceutical industries.

InChI:InChI=1/C8H6F4O/c9-7-3-6(8(10,11)12)2-1-5(7)4-13/h1-3,13H,4H2

Upstream product

• 89763-93-9 2-Fluoro-4-(trifluoromethyl)benzaldehyde 
• 115029-24-8 2-fluoro-4-(trifluoromethyl)benzoic acid 

Downstream Products

• 478373-36-3 {4'-Methoxy-3'-[(2-fluoro-4-trifluoromethylbenzyloxycarbonylamino)methyl]biphenyl-3-yl}acetic acid 
• 478373-56-7 {4'-Ethoxy-3'-[(2-fluoro-4-trifluoromethylbenzyloxycarbonylamino)methyl]biphenyl-3-yl}acetic acid 
• 478373-86-3 2-{4'-Methoxy-3'-[(2-fluoro-4-trifluoromethylbenzyloxycarbonylamino)methyl]biphenyl-3-yl}propionic acid 
• 1000339-60-5 2-fluoro-4-trifluoromethylbenzyl chloride 
• 438046-84-5 Piperazine-1-carbothioic acid S-(2-fluoro-4-trifluoromethyl-benzyl)ester hydrochloride 
• 89763-93-9 2-Fluoro-4-(trifluoromethyl)benzaldehyde 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.